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Kruppel-Like Factor 2 in Cholangiocarcinoma 
 
Cody J. Wehrkamp, and Justin L. Mott 
 
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, 
Omaha NE 
 
Background: Kruppel-like factor 2 (KLF2) is a transcription factor with tumor suppressive 
functions that has dysregulated expression in several cancers. The potential role of KLF2 in 
cholangiocarcinoma is as of yet unknown. 
 
Objective: We sought to investigate functional effects of KLF2 in cholangiocarcinoma and 
hypothesized that KLF2 regulates proliferation, migration and apoptosis in cholangiocarcinoma 
cells. 
 
Methods: Cholangiocarcinoma cell line KMCH was employed as well as Hek293T. Cells were 
stably transfected with KLF2 plasmid containing puromycin selection vector. Proliferation was 
measured using MTT assay. Transwell and scratch assays were used to evaluate migration. 
Apoptosis was induced using either TRAIL or staurosporine and cell death was measured by 
caspase 3/7 activity or nuclear morphology changes. 
 
Results: Expression of KLF2 led to reduced growth by 24 hours in KMCH cells compared to 
parental cells and by 48 hours in Hek293T. KMCH cells with overexpression of KLF2 exhibited 
significantly reduced migration over 72 hours compared to parental cells. Induction of cell death 
in KLF2-expressing KMCH cells led to less apoptosis compared to parental cells. No difference 
was observed in apoptosis resistance between KLF2 transfected Hek293T cells compared to 
parental. 
 
Conclusion: We found that KLF2 expression leads to reduced proliferation and migration as 
well as increased resistance to apoptosis, reflecting an overall more quiescent phenotype. 
Experiments are underway to evaluate KLF2 in an in vivo cholangiocarcinoma model. 
